Does Blue Cross Blue Shield of Alabama Cover Farxiga?

What Is Farxiga and Why Does Coverage Complexity Matter?

Farxiga is the brand name for dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by AstraZeneca. The FDA first approved it in 2014 for type 2 diabetes mellitus, then expanded the label in 2020 to include heart failure with reduced ejection fraction (HFrEF), in 2021 to heart failure with preserved ejection fraction (HFpEF), and in 2021 for chronic kidney disease (CKD) in adults at risk of progression. [1]

Because Farxiga carries three distinct FDA-approved indications beyond glycemic control, patients and prescribers often run into different coverage rules depending on which diagnosis drives the prescription. A prior authorization approved for type 2 diabetes may not automatically extend to CKD or heart failure, even on the same plan.

Why SGLT2 Inhibitors Are on Most Formularies

The American Diabetes Association's 2024 Standards of Care place SGLT2 inhibitors in a Tier 1 recommendation for patients with type 2 diabetes plus established cardiovascular disease, CKD, or heart failure, regardless of baseline HbA1c. [2] That clinical weight means most large insurers, including BCBS Alabama, are expected to carry at least one SGLT2 inhibitor in the preferred-brand tier. Farxiga competes on formulary against empagliflozin (Jardiance) and canagliflozin (Invokana); your specific BCBS plan may prefer one over the others.

What "Prior Authorization" Actually Means Here

Prior authorization (PA) is a written approval your insurer grants before it will pay for the drug. BCBS Alabama typically requires the prescribing physician to submit clinical documentation showing the patient has tried and failed (or has a contraindication to) metformin, and that one of Farxiga's approved indications is confirmed. Without an approved PA, the pharmacy will dispense Farxiga at the full list price, which is roughly $580 to $610 per 30-day supply as of mid-2025.

BCBS Alabama Formulary Structure: Where Does Farxiga Land?

Blue Cross Blue Shield of Alabama uses a multi-tier formulary. Most commercial group plans carry five tiers; most Medicare Advantage plans carry six. Farxiga sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the specific plan design. [3]

Tier 3 vs. Tier 4: The Dollar Difference

On a typical BCBS Alabama commercial plan with a $1,500 individual deductible:

• Tier 3 (preferred brand): $45, $60 copay per 30-day fill after the deductible is met.
• Tier 4 (non-preferred brand): $80, $120 copay per 30-day fill, or 40% coinsurance.

If your plan places Jardiance on Tier 3 and Farxiga on Tier 4, your doctor may be able to request a formulary exception to move Farxiga to preferred-brand cost sharing, provided there is a documented clinical reason you cannot use empagliflozin.

Medicare Advantage Plans

BCBS Alabama's Medicare Advantage products (marketed under the "Blue Advantage" and "MyBlue" banners) file separate formularies with CMS each year. In 2024 and 2025 plan years, Farxiga appeared on the formularies of most BCBS Alabama Medicare Advantage plans at Tier 3 with prior authorization required. The CMS formulary finder at Medicare.gov lets you confirm the exact tier for your specific contract and plan ID.

ACA Marketplace Plans

Under the Affordable Care Act, all non-grandfathered plans must cover drugs on the plan's formulary without discrimination. BCBS Alabama's Bronze, Silver, Gold, and Platinum marketplace plans all carry Farxiga on formulary. However, Bronze plan members often face a deductible of $7,000 or more before the Tier 3 copay kicks in. Patients with Silver plans may qualify for cost-sharing reductions that bring that deductible down significantly.

Prior Authorization Criteria BCBS Alabama Applies to Farxiga

BCBS Alabama's published clinical criteria for SGLT2 inhibitor PA approval typically require all of the following. [4]

Criterion 1: Confirmed Diagnosis

The prescriber must document at least one FDA-approved indication:

• Type 2 diabetes mellitus (ICD-10: E11.x), with HbA1c above 7.0% on current therapy, or
• Heart failure (HFrEF, ejection fraction <40%; or HFpEF, ejection fraction >40%), or
• CKD stage 2 to 4 with albuminuria (urine albumin-to-creatinine ratio >200 mg/g).

Criterion 2: Step Therapy

For the diabetes indication, BCBS Alabama generally requires a documented trial of metformin at the maximally tolerated dose for at least 90 days, unless metformin is contraindicated (eGFR <30 mL/min/1.73 m², or intolerance documented in the medical record).

For the heart failure or CKD indications, step therapy through metformin is generally waived, since those indications are not diabetes-specific. The prescriber should explicitly document which indication drives the request to avoid unnecessary step-therapy denials.

Criterion 3: Prescriber Specialty and Documentation

The PA form typically asks for:

1. Most recent HbA1c, eGFR, urine ACR, or ejection fraction (whichever is relevant).
2. Current medication list confirming step-therapy drugs were tried.
3. Rationale if any step-therapy agent is contraindicated.

A well-documented PA from a cardiologist or nephrologist referencing DAPA-HF or DAPA-CKD trial data has a higher approval rate than a thinly documented submission.

The Clinical Evidence That Supports Coverage Approval

Insurance medical directors review PA requests against published clinical evidence. Citing the right trials in a PA or appeal letter is not optional for patients with complex cases.

DAPA-HF: Heart Failure with Reduced Ejection Fraction

The DAPA-HF trial enrolled 4,744 adults with HFrEF (ejection fraction <40%) and showed that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (HR 0.74; 95% CI 0.65 to 0.85; P<0.001). [5] That magnitude of benefit led multiple cardiology societies to give dapagliflozin a Class I recommendation for HFrEF.

DAPA-CKD: Chronic Kidney Disease

DAPA-CKD enrolled 4,304 adults with CKD (eGFR 25 to 75 mL/min/1.73 m²) and urine ACR of 200 to 5,000 mg/g. Dapagliflozin 10 mg reduced the primary composite endpoint (sustained decline in eGFR >50%, end-stage kidney disease, or renal/cardiovascular death) by 39% vs. Placebo (HR 0.61; 95% CI 0.51 to 0.73; P<0.001). [6] Roughly one-third of enrolled patients did not have diabetes, which is why the FDA extended the CKD label.

DECLARE-TIMI 58: Cardiovascular Outcomes in T2D

The DECLARE-TIMI 58 trial followed 17,160 patients with type 2 diabetes for a median of 4.2 years. Dapagliflozin reduced the rate of hospitalization for heart failure or cardiovascular death by 17% vs. Placebo (HR 0.83; 95% CI 0.73 to 0.95). [7] Including this data in a PA for a patient with T2D and elevated cardiovascular risk can shift a borderline approval.

Step-by-Step: How to Get Farxiga Covered by BCBS Alabama

Getting coverage approved is a process with specific stages. Moving through them in order saves time.

Step 1: Confirm Your Plan's Formulary Tier

Log into your BCBS Alabama member portal at bcbsal.org, or call the member services number on the back of your insurance card. Search for "dapagliflozin" or "Farxiga" in the drug lookup tool. Note the tier and whether PA is listed as a requirement.

Step 2: Have Your Prescriber Submit the PA

Your doctor (or their office) submits the PA request electronically through CoverMyMeds or directly via the BCBS Alabama provider portal. The insurer has 72 hours to respond to an urgent PA and up to 14 days for a standard PA under Alabama insurance regulations.

Step 3: If Denied, Request a Peer-to-Peer Review

A peer-to-peer review is a phone call between your prescribing physician and the insurance company's medical director. Studies show peer-to-peer reviews overturn initial PA denials in 30% to 70% of cases depending on the condition and drug class. Your doctor's office must request this call within the denial notice's stated timeframe, often 14 days.

Step 4: File a Formal Appeal

If the peer-to-peer fails, BCBS Alabama must offer a formal internal appeal. The appeal should include:

• A letter of medical necessity from the prescribing physician.
• Office notes documenting the clinical indication and failed step-therapy drugs.
• Copies of relevant trial abstracts (DAPA-HF, DAPA-CKD, DECLARE-TIMI 58).
• Any ADA or ACC/AHA guideline language recommending SGLT2 inhibitors.

The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, high cardiovascular risk, heart failure, or diabetic kidney disease, an SGLT2 inhibitor with proven cardiovascular or kidney benefit is recommended." [2] Quoting this language directly in an appeal letter gives the medical director a clear guideline anchor.

Step 5: External Appeal or State Complaint

If BCBS Alabama upholds the denial after internal appeal, Alabama law allows an external independent review. File with the Alabama Department of Insurance (ALDOI) at aldoi.gov. Alternatively, if the plan is self-funded (many employer plans are), the Employee Retirement Income Security Act (ERISA) governs the process, and a healthcare attorney may be needed.

How to Reduce Your Out-of-Pocket Cost for Farxiga

Even with coverage, costs can be substantial before a deductible is met.

AstraZeneca's Farxiga Savings Card

AstraZeneca offers a savings card through the Farxiga website for commercially insured patients. Eligible patients may pay as little as $0 per month, with a maximum benefit of $150 per 30-day supply. Medicare and Medicaid patients are not eligible. Income limits do not apply for the commercial card. [8]

AZ&Me Prescription Savings Program

Patients who are uninsured or underinsured and meet income criteria (household income at or below 400% of the federal poverty level) may receive Farxiga at no cost through AstraZeneca's patient assistance program, AZ&Me. Applications are submitted at azandmeapp.com.

GoodRx and Pharmacy Coupons

GoodRx coupons can bring the cash price of Farxiga to approximately $480, $520 per 30-day supply at major Alabama pharmacies. That is still high, but relevant for patients in a deductible period who cannot use the savings card alongside insurance.

Formulary Exception for a Covered Alternative

If BCBS Alabama places a different SGLT2 inhibitor (e.g., empagliflozin) on Tier 3 while Farxiga sits on Tier 4, your physician can request a formulary exception only if there is a clinical reason empagliflozin will not work. Without that documented reason, switching to the preferred SGLT2 inhibitor on your plan is usually the fastest path to lower cost.

Farxiga for Non-Diabetes Indications: Does Coverage Differ?

Coverage rules can shift significantly when dapagliflozin is prescribed for heart failure or CKD rather than diabetes.

Heart Failure Coverage

Cardiologists prescribing Farxiga for HFrEF or HFpEF should submit the PA under the cardiovascular indication explicitly. The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure gives dapagliflozin a Class I, Level of Evidence A recommendation for HFrEF, [9] and that carries weight with BCBS Alabama's pharmacy and therapeutics committee. The step-therapy requirement for metformin does not apply when diabetes is absent.

CKD Coverage

For CKD without diabetes, the prescriber should document the eGFR, urine ACR, and the patient's risk of progression per the KDIGO 2022 CKD guidelines. [10] BCBS Alabama medical policy may require nephrology involvement in the PA, particularly if the eGFR is below 25 mL/min/1.73 m², which was the exclusion threshold in DAPA-CKD.

What Happens If BCBS Alabama Denies Coverage Entirely?

A flat denial is not the end of the road. Three options remain.

Therapeutic Substitution

BCBS Alabama may cover a different SGLT2 inhibitor on a more favorable tier. Empagliflozin (Jardiance) has similar evidence in HFrEF (EMPEROR-Reduced, N=3,730) [11] and CKD (EMPA-KIDNEY, N=6,609). [12] If your prescriber is comfortable with the substitution, switching drugs resolves the coverage issue immediately.

Manufacturer Patient Assistance

AZ&Me can cover Farxiga entirely for qualifying patients regardless of insurance status. The application process takes approximately 2 to 4 weeks, so start early.

Off-Label Use Considerations

Dapagliflozin has no FDA-approved off-label uses that carry strong insurance coverage precedent beyond the three approved indications. Prescribing for an off-label condition almost always results in a denial with limited appeal options.

BCBS Alabama vs. Other BCBS Plans: Is Coverage the Same?

Blue Cross Blue Shield of Alabama is a separate, independent licensee of the BCBS Association. Its formularies, PA criteria, and tiering decisions are set in Montgomery, Alabama, not by the national BCBS Association. A patient with BCBS of Texas, BCBS of Illinois, or Anthem (a different BCBS licensee) will face completely different PA criteria and formulary tiers for Farxiga.

If you recently moved to Alabama from another state, do not assume your prior authorization in your old state transfers. You must re-submit the PA to BCBS Alabama through a licensed Alabama provider.

Key Takeaways for Patients and Prescribers

Patients prescribed Farxiga under a BCBS Alabama plan should take these concrete actions before the first prescription is sent to the pharmacy.

1. Verify Farxiga's formulary tier in the BCBS Alabama member portal before the prescription is written.
2. Ask the prescribing office to submit a PA simultaneously with sending the prescription, so the pharmacy hold does not create a treatment gap.
3. Download the AstraZeneca savings card from the Farxiga website to cover any cost-sharing while the PA is pending.
4. If the PA is denied, request a peer-to-peer review within 72 hours of the denial notice to preserve the appeal window.

The 2024 ADA Standards of Care are explicit: for patients with type 2 diabetes and heart failure, "an SGLT2 inhibitor with proven benefit is recommended to reduce the risk of heart failure hospitalization and cardiovascular death." [2] Your insurer's PA process is not designed to override that recommendation permanently. It is designed to confirm medical necessity. A well-prepared submission from a physician who has documented the clinical indication and failed first-line therapies will resolve most Farxiga PA requests within 14 days.